🇺🇸 FDA
Patent

US 6863887

Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

expired A61KA61K2039/505A61K38/00

Quick answer

US patent 6863887 (Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis) held by Northwest Biotherapeutics, Inc. expires Mon Mar 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Northwest Biotherapeutics, Inc.
Grant date
Tue Mar 08 2005 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K38/00